Last10K.com

Gilead Sciences Inc (GILD) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

Gilead Sciences Inc

CIK: 882095 Ticker: GILD



gileadlogocolora001a18.jpg
CONTACTS:
Investors
 
 
Media
 
Andrew Dickinson
 
 
Amy Flood
 
(650) 524-0862
 
 
(650) 522-5643
 
 
 
 
 
 
Douglas Maffei, Ph.D.
 
 
 
 
(650) 522-2739
 
 
 
 
 
 
 
 
For Immediate Release

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

- Product Sales of $5.5 billion -
- Diluted EPS of $1.22 per share -
- Non-GAAP Diluted EPS of $1.68 per share -

Foster City, CA, April 30, 2020 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2020.
“Gilead’s performance during the first quarter demonstrates our continued progress and highlights the strength of our underlying business. While we are prepared to navigate the uncertainty and short-term impact from the pandemic, we are confident in our ability to deliver on our long-term goals,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “Our focus at this time is on both our work with remdesivir and our ongoing commitments to the people who depend on our medicines today.”
First Quarter Financial Results
The financial results that follow represent a year-over-year comparison of the first quarter 2020 to the first quarter 2019. Total revenues for the first quarter 2020 were $5.5 billion, an increase of 5% compared to the same period in 2019. Net income for the first quarter 2020 was $1.6 billion or $1.22 per diluted share, a decrease of 21% compared to the same period in 2019. Non-GAAP net income for the first quarter 2020 was $2.1 billion or $1.68 per diluted share, essentially flat compared to the same period in 2019.
 
 
Three Months Ended
 
 
March 31,
(In millions, except per share amounts)
 
2020
 
2019
Product sales
 
$
5,467

 
$
5,200

Royalty, contract and other revenues
 
81

 
81

Total revenues
 
$
5,548

 
$
5,281

 
 
 
 
 
Net income attributable to Gilead
 
$
1,551

 
$
1,975

Non-GAAP net income attributable to Gilead
 
$
2,139

 
$
2,141

 
 
 
 
 
Diluted earnings per share
 
$
1.22

 
$
1.54

Non-GAAP diluted earnings per share
 
$
1.68

 
$
1.67

________________________________
Starting in 2020, Gilead no longer regularly excludes share-based compensation expense from its non-GAAP financial information. To conform to this change, the prior period non-GAAP financial information has been recast to include share-based compensation expense. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 9 and 10.

- more -

Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA
www.gilead.com
phone (650) 574-3000 facsimile (650) 578-9264
 

The following information was filed by Gilead Sciences Inc (GILD) on Thursday, April 30, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Gilead Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Gilead Sciences Inc.

Continue

Assess how Gilead Sciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Gilead Sciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Legal
Other
Filter Subcategory:
All
Expense
Product
Earnings
Debt
Geography
Income
Other
Inside Gilead Sciences Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Income
Condensed Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parenthetical)
Acquisition, Collaborations And Other Arrangements
Acquisition, Collaborations And Other Arrangements Forty Seven (Details)
Available-For-Sale Debt Securities
Available-For-Sale Debt Securities (Tables)
Available-For-Sale Debt Securities - Additional Information (Details)
Available-For-Sale Debt Securities - Summary Of Available-For-Sale Debt Securities At Estimated Fair Value (Details)
Available-For-Sale Debt Securities - Summary Of Available-For-Sale Debt Securities By Contractual Maturity (Details)
Available-For-Sale Debt Securities - Summary Of Available-For-Sale Debt Securities In A Continuous Unrealized Loss Position (Details)
Available-For-Sale Debt Securities - Summary Of The Balance Sheet Classification Of Available-For-Sale Debt Securities (Details)
Collaborations And Other Arrangements Narrative (Details)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Details)
Debt And Credit Facilities
Debt And Credit Facilities (Tables)
Debt And Credit Facilities Additional Information (Details)
Debt And Credit Facilities Summary Of Debt Carrying Amount (Details)
Derivative Financial Instruments
Derivative Financial Instruments (Tables)
Derivative Financial Instruments - Additional Information (Details)
Derivative Financial Instruments - Summary Of Classification And Fair Value Of Derivative Instruments (Details)
Derivative Financial Instruments - Summary Of Effect Of Foreign Currency Exchange Contracts (Details)
Derivative Financial Instruments - Summary Of Potential Effect Of Offsetting Derivatives (Details)
Disaggregation Of Revenues (Tables)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements Additional Information (Details)
Fair Value Measurements Summary Of Assets And Liabilities Measured At Fair Value (Details)
Fair Value Measurements Summary Of Classification Of Other Equity Securities On Balance Sheet (Details)
Income Taxes
Income Taxes (Details)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Details)
Intangible Assets - Schedule Of Estimated Future Amortization Expense (Details)
Intangible Assets - Summary Of Intangible Assets (Details)
Net Income Per Share Attributable To Gilead Common Stockholders
Net Income Per Share Attributable To Gilead Common Stockholders (Tables)
Net Income Per Share Attributable To Gilead Common Stockholders - Additional Information (Details)
Net Income Per Share Attributable To Gilead Common Stockholders - Schedule Of The Calculation Of Basic And Diluted Eps (Details)
Other Financial Information
Other Financial Information (Tables)
Other Financial Information Inventories (Details)
Other Financial Information Other Accrued Liabilities (Details)
Revenues
Revenues (Details)
Revenues Contract Assets (Details)
Revenues Revenues From Major Customers (Details)
Revenues Revenues From Major Customers (Tables)
Revenues Revenues Recognized From Performance Obligations Satisfied In Prior Periods (Details)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity Stock Repurchase Program (Details)
Stockholders' Equity Summary Of Changes In Accumulated Other Comprehensive Income (Loss) (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies Additional Details (Details)
Ticker: GILD
CIK: 882095
Form Type: 10-Q Quarterly Report
Accession Number: 0000882095-20-000013
Submitted to the SEC: Tue May 05 2020 7:03:19 PM EST
Accepted by the SEC: Wed May 06 2020
Period: Tuesday, March 31, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/gild/0000882095-20-000013.htm